Both are injected once weekly using pre-filled pens, come in escalating dose strengths (2.5 mg to 15 mg), and are manufactured under FDA Current Good Manufacturing Practice (CGMP) standards
Monami M, Cremasco F, Lamanna C, et al
doi: 10.1016/j.biopha.2018.08.088 93 Yildirim SimsirISoyaltinUECetinkalpS
Nurses must learn all they can about these novel medications and their adverse effects, risks, and benefits, as well as their compounded substitutes
The answer depends on individual circumstances
Developed by Eli Lilly and Company, Orforglipron is the first oral, non-peptide GLP-1 receptor agonistremoving one of the biggest barriers in diabetes & obesity care: injectables